See how well these 20 sisters are doin’ it for themselves. [© stefa_neve - Fotolia.com]
#10. Jacqualyn A. Fouse, Ph.D.
Company: Celgene
Title: EVP and CFO
2012 Compensation: $3,450,103
2011 Compensation: $2,535,033
% Change: 36.1%
#9. Robin L. Washington
Company: Gilead Sciences
Title: SVP and CFO
2012 Compensation: $4,175,593
2011 Compensation: $4,032,193
% Change: 3.6%
#8. Sandra Peterson
Company: Johnson & Johnson
Title: Group Worldwide Chair
2012 Compensation: $4,698,8506
2011 Compensation: N/A6
% Change: N/A6
#7. Silvia Ayyoubi
Company: Roche
Title: Head, Group Human Resources
2012 Compensation: $5,346,932 (CHF 4,970,897)1
2011 Compensation: $4,342,348 (CHF 4,037,074)1,7
% Change: 23.1%
#6. Amy W. Schulman
Company: Pfizer
Title: EVP and General Counsel; Business Unit Lead, Consumer Healthcare
2012 Compensation: $5,573,218
2011 Compensation: $5,764,662
% Change: -3.3%
#5. Sandra Leung
Company: Bristol-Myers Squibb
Title: General Counsel & Corporate Secretary
2012 Compensation: $5,892,772
2011 Compensation: $5,491,673
% Change: 7.3%
#4. Martine Rothblatt
Company: United Therapeutics
Title: CEO
2012 Compensation: $7,958,328
2011 Compensation: $3,161,350
% Change: 151.7%
#3. Heather Bresch
Company: Mylan
Title: CEO
2012 Compensation: $8,000,628
2011 Compensation: $9,208,0348
% Change: -13.1%
#2. Beatrice Cazala
Company: Bristol-Myers Squibb
Title: EVP, Commercial Operations
2012 Compensation: $8,031,025
2011 Compensation: $5,941,1679
% Change: 35.2%
#1. Laura J. Schumacher
Company: AbbVie
Title: EVP, Business Development, External Affairs and General Counsel
2012 Compensation: $10,192,74810
2011 Compensation: $5,567,49310
% Change: 83.1%
Notes:
1 Figures converted to U.S. Dollars via www.xe.com on August 2, 2013.
2 Served in current position since January 2012. Previously served as VP, Corporate Communications and Investor Relations, a position she had held since July 2008, when she joined the company from Genzyme.
3 Joined company in December 2011.
4 Joined company in September 2011.
5 Dr. Dipp received no compensation in 2011, but did receive 701,927 shares of common stock in April 2011 in connection with her role as a founder of our company, for an aggregate purchase price of $1,420.
6 Joined Johnson & Johnson on December 1, 2012.
7 Figure varies from dollar amount reported last year, $4,035,692, due to currency fluctuation.
8 CEO appointment took effect January 1, 2012. She previously served as president, a position she had held since July 2009.
9 Became a named officer of Bristol-Myers Squibb in February 2011, after previously serving the company on a short-term U.S. assignment as a French expatriate. As a result, her 2011 compensation includes a payout of her accrued vacation with the company’s French subsidiary as required by French law.
10 AbbVie comprises the branded pharmaceutical operations spun out of Abbott Laboratories on January 2, 2013. 2012 and 2011 compensation figures reflect Ms. Schumacher’s position both years as Abbott’s evp, general counsel, and corporate secretary.
To enjoy more articles like this from GEN, click here to subscribe now!